Disturbo da uso di alcol e terapie farmacologiche: a che punto siamo?

Journal title MISSION
Author/s Marco Riglietta
Publishing Year 2024 Issue 2024/67
Language Italian Pages 8 P. 25-32 File size 0 KB
DOI 10.3280/mis67-2024oa18338
DOI is like a bar code for intellectual property: to have more infomation click here

View article Download Open Access article

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Alcohol use disorder has a complex aetiology, pathogenesis and clinical manifestation in which genetic mechanisms, traumatic histories, social and family context determine the evolution of the disease and the possibility of remission of the same. On the other hand, other pathologies, much more widespread in Western society, diabetes or hypertension for example, share the same etiological complexity, pathogenesis and clinical manifestations. The intervention on these pathologies is certainly pharmacological but not only: it is accompanied by a motivational intervention, continuous counselling to monitor adherence to therapies, often overlapping with a psychoeducational intervention with nutritional as well as behavioural indications (physical activity). Surely a diabetic or a hypertensive will have a pharmacological prescription in almost all cases; in alcoholology only 30% of patients have a prescribed pharmacological therapy and often these are drugs that do not have a specific indication (anxiolytics, antidepressants etc.) In short, "alcoholics" are treated, essentially, with a psycho-socio-educational intervention.

Keywords: ; Alcohol Use Disorder; Alcohol Drugs; Alcohol Treatment; SerD; Noa

  1. Relazione del Ministro della Salute al Parlamento sugli interventi realizzati ai sensi della legge 30.3.2001 n. 125 “legge quadro in materia di alcol e problemi alcol correlati” anno 2023. www.salute.gov.it/imgs/C_17_pubblicazioni_3459_allegato.pdf.
  2. Codifa L’informatore Farmaceutico 2024 – www.codifa.it.
  3. Fortinguerra et al. (2023). The use of medications approved for alcohol use disorders in Italy. Front. Public Health, 15 February. DOI: 10.3389/fpubh.2023.1110435
  4. Rehm J. et al. (2018). Alcohol dependence and very highrisk level of alcohol consumption: a life-threatening and debilitating disease. Addict Biol, Jul, 23(4): 961-968 DOI: 10.1111/adb.12646
  5. World Health Organization (WHO) (2000) International Guide for Monitoring Alcohol Consumption and Related Harm. World Health Organization, Geneva, Switzerland.
  6. van den Brink W. et al. (2014). Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study, J Psychopharmacol, Aug, 28(8): 733-44. DOI: 10.1177/0269881114527362
  7. Witkiewitz K. et al. (2017). Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res, Jan, 41(1): 179-186. DOI: 10.1111/acer.13272. Epub 2016 Dec 26
  8. Hasin D.S. et al. (2017). Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year followup study in the US general population. Lancet Psychiatry, Jun, 4(6): 469-476. DOI: 10.1016/S2215-0366(17)30130-X. Epub 2017 Apr 26
  9. Helping people who drink too much - A clinician guide - US National Institute on alcohol abuse and alcoholism – 2005.
  10. Alcohol Use Disorder; diagnosis assessment and management of harmful drinking (high risk drinking) and alcohol dependence - Clinical guideline. Published: 23 February 2011. Last updated: 21 October 2014 – National Institute for health and care excellence (NICE).
  11. European Medicines Agency (2010). Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence. European Medicines Agency, London, UK.
  12. Food and Drug Administration (2015). Alcoholism: Developing Drugs for Treatment (No. FDA D-0152-001). Food and Drug Administration, Silver Spring, MD.
  13. Sullivan et al. (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, Nov, 84(11): 1353-7. DOI: 10.1111/j.1360-0443.1989.tb00737.x
  14. Protracted Withdrawal U.S. department of health and human services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment www.samhsa.gov, July 2010, 9(1).
  15. Caputo F. et al. (2019). Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. Intern Emerg Med, Jan, 14(1): 143-160. DOI: 10.1007/s11739-018-1933-8. Epub 2018 Sep 5
  16. Heilig M. et al. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?. Addiction Biology, 15: 169-z84. DOI: 10.1111/j.1369-1600.2009.00194.x
  17. Gallus S. et al. (2023). Symptoms of Protracted Alcohol Withdrawal in Patients with Alcohol Use Disorder: A Comprehensive Systematic Review, 21(2): 409-416. DOI: 10.2174/1570159X20666220706105253
  18. INTERCHECK Web Istituto di ricerche farmacologiche Mario Negri IRCSS, https://intercheckweb.marionegri.it.

Marco Riglietta, Disturbo da uso di alcol e terapie farmacologiche: a che punto siamo? in "MISSION" 67/2024, pp 25-32, DOI: 10.3280/mis67-2024oa18338